A cross-sectional study of selective serotonin reuptake inhibitor (SSRI) use by community-dwelling older women aged ≥71 years with or without depression demonstrated that SSRI use in that population was strongly associated with sleep disturbance. The study, which relied on data collected from 4 centers throughout the United States, was recently published in the Journal of the American Geriatrics Society.
A cross-sectional study of selective serotonin reuptake inhibitor (SSRI) use by community-dwelling older women aged ≥71 years with or without depression demonstrated that SSRI use in that population was strongly associated with sleep disturbance. The study, which relied on data collected from 4 centers throughout the United States, was recently published in the Journal of the American Geriatrics Society.
Depressive symptoms and depression have been related to sleep complaints in older individuals, perhaps due to other psychiatric/medical problems or medication effects. SSRIs are commonly prescribed antidepressants due to their perceived limited adverse effect profile. Studies have assessed overnight sleep electroencephalographic (EEG) recordings of SSRI users, and the agents' effects on sleep generally have been negative (eg, rapid-eye-movement [REM] suppression, prolongation of REM latency, poor sleep efficiency, and greater nighttime wakefulness).
The cohort of 10,336 women consisted of Caucasian and Black women from the Study of Osteoporotic Fractures (SOF). In the study sample, SSRI use was ascertained, evidence of depression was assessed via patient query, and objective measures of sleep were taken using wrist actigraphy for a minimum of 3 days and nights. All active surviving study participants (n=3,047) were asked to participate in an examination that included women who had complete actigraphy and medication information. After additional exclusions, the overall cohort included 2,853 women. A secondary analysis was performed in 2,337 women with a depression diagnosis or in those who scored ≥6 on a 15-item Geriatric Depression Scale (GDS)-a self-reported scale of 15 yes/no questions regarding depression symptoms, with 6 symptoms being the depression cutoff. The Goldberg anxiety scale also was used.
Patients kept a sleep log, and the following sleep parameters (average for all nights) also were examined: total sleep time per night; sleep efficiency; sleep latency; time awake after sleep onset; and long wake episodes (number of awakenings >5 minutes).
The mean age of the overall cohort was 83 years, with 8% (n=223) taking SSRIs and 2,630 not taking antidepressants. Of the nondepressed subcohort (n=2,337), 3% (n=69) were taking SSRIs and 2,268 were not taking antidepressants. The overall cohort had low total sleep time (9% with ≤5 hours sleep), sleep efficiency of <70% (21%), long sleep latency (≥1 hour), and high nighttime wakefulness (30% after sleep onset of ≥1.5 hours); 27% had ≥8 long wake episodes.
After adjustments for confounders, women taking SSRIs were more likely than those not receiving antidepressants to have sleep duration of ≤5 hours (multivariate OR=2.15; 95% CI, 1.04–4.47), sleep efficiency of <70% (multivariate OR=2.37; 95% CI, 1.32–4.25), sleep latency of ≥1 hour (multivariate OR=3.99; 95% CI, 2.29–6.96), and number of long wake episodes ≥8 (multivariate OR=1.75; 95% CI, 0.99–3.10); impaired sleep continued in the subcohort of nondepressed women. After adjustment for multiple potential confounders, women without a diagnosis of depression (SSRI users) on average still had impaired sleep. Average sleep time was similar between SSRI users and non-antidepressant users (P=.33).
Study limitations included lack of a control group and potential confounding by indication (SSRI use may be an indicator for depression, depressive symptoms, or anxiety, which itself can impair sleep). Additionally, extrapolation to other populations may be inaccurate, and self-reported parameters also may be inaccurate (eg, time out of bed).
SOURCE Ensrud KE, Blackwell TL, Ancoli-Israel S, et al; for the Study of Osteoporotic Fractures Research Group. Use of selective serotonin reuptake inhibitors and sleep disturbances in community-dwelling older women. J Am Geriatr Soc. 2006;54:1508–1515.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.